Search Results - "Musick, Lisa"

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data by Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew, Ozcan, Muhit, Safar, Violaine, Salles, Gilles, Ku, Grace, Hirata, Jamie, Chang, Yi Meng, Musick, Lisa, Matasar, Matthew J.

“…Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)…”
Get full text

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study by Flowers, Christopher R, Matasar, Matthew J, Herrera, Alex F, Hertzberg, Mark, Assouline, Sarit, Demeter, Judit, McMillan, Andrew, Mehta, Amitkumar, Opat, Stephen, Trnňný, Marek, Musick, Lisa, Hirata, Jamie, Yang, Annie, Sehn, Laurie H

“…Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with…”
Get full text

POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma by Matasar, Matthew J., Haioun, Corinne, Sancho, Juan-Manuel, Viardot, Andreas, Hirata, Jamie, Perretti, Thomas, Musick, Lisa, McMillan, Andrew K

“…Background: Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b on malignant B-cells. Polatuzumab vedotin in combination with bendamustine and…”
Get full text

Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography by Jemaa, Skander, Ounadjela, Souhila, Wang, Xiaoyong, El-Galaly, Tarec C, Kostakoglu, Lale, Knapp, Andrea, Ku, Grace, Musick, Lisa, Sahin, Denis, Wei, Michael C, Yin, Shen, Bengtsson, Thomas, De Crespigny, Alex, Carano, Richard A D

“…Artificial intelligence can reduce the time used by physicians on radiological assessments. For 18F-fluorodeoxyglucose-avid lymphomas, obtaining complete…”
Get full text

Automated Lugano Metabolic Response Assessment in 18 F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18 F-Fluorodeoxyglucose-Positron Emission Tomography by Jemaa, Skander, Ounadjela, Souhila, Wang, Xiaoyong, El-Galaly, Tarec C, Kostakoglu, Lale, Knapp, Andrea, Ku, Grace, Musick, Lisa, Sahin, Denis, Wei, Michael C, Yin, Shen, Bengtsson, Thomas, De Crespigny, Alex, Carano, Richard A D

“…Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-fluorodeoxyglucose-avid lymphomas, obtaining complete…”
Get full text

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study by Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew K., Özcan, Muhit, Safar, Violaine, Salles, Gilles, Hirata, Jamie, Yang, Annie, Musick, Lisa, Matasar, Matthew J.

Get full text

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update by Diefenbach, Catherine S., Kahl, Brad S., Banerjee, Lalita, McMillan, Andrew K., Miall, Fiona, Briones, Javier, Cordoba, Raul, Burke, John M., Hirata, Jamie, Sharma, Sunil, Musick, Lisa, Abrisqueta Costa, Pau

Get full text

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma by Yuen, Sam, Phillips, Tycel J., Bannerji, Rajat, Marlton, Paula, Gritti, Giuseppe, Seymour, John F., Johnston, Anna, Arthur, Christopher, Dodero, Anna, Sharma, Sunil, Hirata, Jamie, Musick, Lisa, Flowers, Christopher R.

“…The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed‐dose obinutuzumab 1000 mg or…”
Get full text

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) by Matasar, Matthew J., Haioun, Corinne, Sancho, Juan-Manuel, Viardot, Andreas, Rodriguez Izquierdo, Antonia, Donato Martin, Eva Maria, Garcia-Sancho, Alejandro Martin, Sandoval-Sus, Jose David, Tilly, Herve, Vandenberghe, Elizabeth, Hirata, Jamie, Choudhry, Priya, Chang, Yi Meng, Musick, Lisa, McMillan, Andrew

“…7551 Background: Transplant-ineligible pts with R/R DLBCL have a poor prognosis (Gisselbrecht C, et al. Br J Haematol 2018). Several treatment options are…”
Get full text

Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA by Herrera, Alex F., Tracy, Samuel, Croft, Brandon, Opat, Stephen, Ray, Jill, Musick, Lisa, Paulson, Joseph N., Sehn, Laurie H., Jiang, Yanwen

“…Introduction Early identification of patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) at high risk for treatment failure…”
Get full text

Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use by Long-Boyle, Janel R, Savic, Rada, Yan, Shirley, Bartelink, Imke, Musick, Lisa, French, Deborah, Law, Jason, Horn, Biljana, Cowan, Morton J, Dvorak, Christopher C

“…Population pharmacokinetic (PK) studies of busulfan in children have shown that individualized model-based algorithms provide improved targeted busulfan…”
Get full text

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial by Magid Diefenbach, Catherine S., Abrisqueta, Pau, Gonzalez-Barca, Eva, Panizo, Carlos, Arguinano Perez, Jose Maria, Miall, Fiona, Bastos-Oreiro, Mariana, Lopez-Guillermo, Armando, Banerjee, Lalita, McMillan, Andrew, Hirata, Jamie, Musick, Lisa, Saha, Sourish, Croft, Brandon, Seymour, Erlene Kuizon

“…Abstract only 7512 Background: The combination of Pola-R-Len may enhance anti-tumor response in R/R DLBCL. We report the primary analysis of the R/R DLBCL…”
Get full text

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial by Bannerji, Rajat, Yuen, Sam, Phillips, Tycel Jovelle, Arthur, Christopher, Isufi, Iris, Marlton, Paula, Seymour, John Francis, Corradini, Paolo, Molinari, Annalia, Gritti, Giuseppe, Emmons, Robert, Hirata, Jamie, Musick, Lisa, Saha, Sourish, Croft, Brandon, Flowers, Christopher

“…Abstract only 7534 Background: Polatuzumab vedotin (Pola) + obinutuzumab (G) demonstrated activity and tolerability in a Phase 1b/2 trial of patients (pts)…”
Get full text

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial by Diefenbach, Catherine, Kahl, Brad S., Banerjee, Lalita, McMillan, Andrew K, Miall, Fiona, Briones, Javier, Cordoba, Raul, Hirata, Jamie, Chang, YiMeng, Musick, Lisa, Abrisqueta, Pau

“…▪ Introduction: Polatuzumab vedotin (Pola) combined with obinutuzumab (G) demonstrated activity and tolerability in a Phase Ib/II trial of patients (pts) with…”
Get full text

Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1 by Amin, Dhara N., Oeh, Jason, Zindal, Anuradha, Musick, Lisa, Hirata, Jamie, Mobasher, Mehrdad, Polson, Andy, Sampath, Deepak, Wertz, Ingrid E.

“…Abstract Venetoclax, a potent, orally bioavailable inhibitor that selectively targets BCL-2 and induces intrinsic apoptosis, is currently approved for the…”
Get full text

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study by Gritti, Giuseppe, Marlton, Paula, Phillips, Tycel J., Arthur, Christopher, Bannerji, Rajat, Corradini, Paolo, Johnston, Anna, Seymour, John F., Yuen, Sam, Hirata, Jamie, Musick, Lisa, Saha, Sourish, Croft, Brandon, Flowers, Christopher

“…Introduction: Polatuzumab vedotin (Pola) combined with rituximab (R) demonstrated activity and tolerability in a Phase (Ph) II trial of patients (pts) with…”
Get full text

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension by Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit E, Flowers, Christopher, Kim, Tae Min, McMillan, Andrew, Ozcan, Muhit, Safar, Violaine, Salles, Gilles, Musick, Lisa, Hirata, Jamie, Chang, YiMeng, Ku, Grace, Matasar, Matthew J

“…Introduction: Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting CD79b on B-cell non-Hodgkin lymphoma. In the randomized cohort of…”
Get full text

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study by Lasater, Elisabeth A., Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Barrett, Kathy, Rys, Ryan N., Oeh, Jason, Lin, Eva, Sterne‐Weiler, Tim, Ingalla, Ellen Rei, Go, MaryAnn, Yu, Shang‐Fan, Krem, Maxwell M., Arthur, Chris, Hahn, Uwe, Johnston, Anna, Karur, Vinit, Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Polson, Andrew G., Chang, YiMeng, Wever, Claudia, Johnson, Nathalie A., Jiang, Yanwen, Hirata, Jamie, Sampath, Deepak, Musick, Lisa, Flowers, Christopher R., Wertz, Ingrid E.

“…The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro‐survival BCL‐2…”
Get full text

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study by Diefenbach, Catherine, Kahl, Brad S, McMillan, Andrew, Briones, Javier, Banerjee, Lalita, Cordoba, Raul, Miall, Fiona, Burke, John M, Hirata, Jamie, Jiang, Yanwen, Paulson, Joseph N, Chang, Yi Meng, Musick, Lisa, Abrisqueta, Pau

“…Obinutuzumab with polatuzumab vedotin or lenalidomide showed tolerability and activity in phase 1b/2 trials that recruited patients with relapsed or refractory…”
Get full text

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA by Herrera, Alex F., Tracy, Samuel, Croft, Brandon, Opat, Stephen, Ray, Jill, Lovejoy, Alex F., Musick, Lisa, Paulson, Joseph N., Sehn, Laurie H., Jiang, Yanwen

“…Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed with…”
Get full text